Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-06-22
Based on 436 first isolates · GER · Cystitis (lower UTI) · 2024-06-23 → 2025-06-22
Geriatrics
Per-organism detail: GER urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 83 % (79 %–86 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (6 %), Klebsiella pneumoniae (5 %), Pseudomonas aeruginosa (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
84 %
90 %
n = 40
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
83 %
80 %
n = 40
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
80 %
88 %
n = 40
mecillinam MEC
trend · Escherichia coli lower UTI only
76 %
83 %
n = 40
ceftriaxone CRO
trend · Escherichia coli
75 %
85 %
n = 40
ciprofloxacin CIP
trend · Escherichia coli
75 %
80 %
n = 40
71 %
83 %
n = 40
trimethoprim TMP
trend · Escherichia coli lower UTI only
68 %
63 %
n = 40
49 %
50 %
n = 40
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
14 %
8 %
n = 40
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
5 %
0 %
n = 40
4 %
5 %
n = 40

Most likely organisms for this profile

Escherichia coli
57 %
Klebsiella pneumoniae
10 %
Enterococcus faecalis
9 %
Proteus mirabilis
6 %
Staphylococcus aureus
5 %
Pseudomonas aeruginosa
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.